[go: up one dir, main page]

PH12013502080A1 - Modified release pharmaceutical compositions of desvenlafaxine - Google Patents

Modified release pharmaceutical compositions of desvenlafaxine

Info

Publication number
PH12013502080A1
PH12013502080A1 PH1/2013/502080A PH12013502080A PH12013502080A1 PH 12013502080 A1 PH12013502080 A1 PH 12013502080A1 PH 12013502080 A PH12013502080 A PH 12013502080A PH 12013502080 A1 PH12013502080 A1 PH 12013502080A1
Authority
PH
Philippines
Prior art keywords
modified release
desvenlafaxine
release pharmaceutical
pharmaceutical compositions
relates
Prior art date
Application number
PH1/2013/502080A
Inventor
Makrand Avachat
Shrenik Kole
Ashok Kumar Sahoo
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of PH12013502080A1 publication Critical patent/PH12013502080A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

This present invention relates to modified release pharmaceutical composition comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof. More particularly, the invention relates to modified release pharmaceutical compositions comprising Desvenlafaxine Benzoate and a process for preparation thereof. Further, the invention relates to a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof wherein Cmax and AUC of the modified release composition are independent of food effect.
PH1/2013/502080A 2011-04-12 2012-04-11 Modified release pharmaceutical compositions of desvenlafaxine PH12013502080A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN530KO2011 2011-04-12
PCT/IB2012/051761 WO2012140577A1 (en) 2011-04-12 2012-04-11 Modified release pharmaceutical compositions of desvenlafaxine

Publications (1)

Publication Number Publication Date
PH12013502080A1 true PH12013502080A1 (en) 2017-01-04

Family

ID=46062650

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2013/502080A PH12013502080A1 (en) 2011-04-12 2012-04-11 Modified release pharmaceutical compositions of desvenlafaxine

Country Status (6)

Country Link
KR (1) KR20140030156A (en)
AU (1) AU2012241407B2 (en)
BR (1) BR112013025766A2 (en)
MX (1) MX2013011884A (en)
PH (1) PH12013502080A1 (en)
WO (1) WO2012140577A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104352469A (en) * 2014-11-20 2015-02-18 哈尔滨圣吉药业股份有限公司 Desvenlafaxine succinate sustained-release tablets and preparation method thereof
TR201820634A2 (en) * 2018-12-27 2020-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DESVENLAFAXINE

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US6197828B1 (en) 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
JP2003521470A (en) 1999-04-06 2003-07-15 セプラコア インコーポレーテッド Derivatives of venlafaxine and methods for their preparation and use
DE60221642T3 (en) 2001-02-12 2017-10-26 Wyeth LLC (n.d.Ges.d. Staates Delaware) O-DESMETHYL-VENLAFAXINE SUCCINATE SALT
US7001920B2 (en) 2002-06-10 2006-02-21 Wyeth Formate salt of O-desmethyl-venlafaxine
CA2554559A1 (en) 2004-02-06 2005-08-25 Wyeth Multiparticulate o-desmethylvenlafaxine salts and uses thereof
CA2601898A1 (en) * 2005-03-31 2006-10-05 Wyeth O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof
US20070014859A1 (en) 2005-07-15 2007-01-18 Wyeth Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate
US7820716B2 (en) 2007-01-08 2010-10-26 Mai De Ltd Crystalline polymorphs of desvenlafaxine succinate and their preparations
CA2692738A1 (en) 2007-07-12 2009-01-15 Dr. Reddy's Laboratories, Ltd. O-desmethylvenlafaxine
WO2009017813A1 (en) 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
CA2702664A1 (en) * 2007-10-16 2009-04-23 Alphapharm Pty Ltd Controlled-release pharmaceutical formulation
EP2212275A2 (en) 2007-10-22 2010-08-04 Actavis Group PTC EHF Solid forms of (±)-o-desmethylvenlafaxine salts
EP2085377A1 (en) 2008-01-29 2009-08-05 LEK Pharmaceuticals D.D. Novel salts of O-desmethyl-venlafaxine
KR100965527B1 (en) 2008-05-08 2010-06-23 제일약품주식회사 Novel (4- (2- (dimethylamino) -1- (1-hydroxycyclohexyl) ethyl) phenoxy) phosphate or a pharmaceutically acceptable salt thereof, preparation method thereof and central nervous system disease containing the same as an active ingredient Prevention and Treatment Composition
WO2010008735A2 (en) 2008-06-16 2010-01-21 Teva Pharmaceutical Industries Ltd. Solid states of o-desmethylvenlaf axine salts

Also Published As

Publication number Publication date
NZ609568A (en) 2015-10-30
AU2012241407B2 (en) 2015-02-05
WO2012140577A1 (en) 2012-10-18
AU2012241407A1 (en) 2013-05-02
BR112013025766A2 (en) 2016-12-20
MX2013011884A (en) 2013-11-21
KR20140030156A (en) 2014-03-11

Similar Documents

Publication Publication Date Title
MX348823B (en) Stable formulations of linaclotide.
WO2011130615A3 (en) Preparation of lacosamide
MX364229B (en) COMPOSITIONS and METHODS FOR TREATING CARDIOVASCULAR DISEASES.
MX342807B (en) Pharmaceutically acceptable cocrystals of n-[2-(7-methoxy-1-napht yl)ethyl]acetamide and methods of their preparation.
WO2010092090A3 (en) Novel salts of sitagliptin
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
MX359288B (en) Ivabradine hydrochloride form iv.
MX2014004196A (en) Rasagiline citramide.
WO2011089126A3 (en) Novel retigabine composition
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
WO2010082220A3 (en) Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
WO2012101653A3 (en) Modified release pharmaceutical compositions memantine
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2010049449A3 (en) Novel salts of sunitinib
MD4563B1 (en) Co-micronisation product comprising ulipristal acetate
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
AU2012277905A8 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
WO2011064558A3 (en) Pharmaceutical composition
UA105285C2 (en) Solid pharmaceutical composition comprising ramipril and amlodipine besilate and method for its preparation
PH12013501900A1 (en) Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
WO2014006636A3 (en) Stable compositions of fesoterodine
PH12013502080A1 (en) Modified release pharmaceutical compositions of desvenlafaxine
PH12013500980A1 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
WO2014007549A3 (en) Composition for preventing or treating colitis comprising s-allyl-l-cysteine as active ingredient, and medical preparation comprising same
WO2011107921A3 (en) Modified release composition of milnacipran